Pharvaris N.V. (PHVS)

$20.35 1.36 (6.26%)

16:00 EDT PHVS Stock Quote Delayed 30 Minutes

PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024

By InvestorPlace Earnings May 8, 2024

PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024.

PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023

Why Is Pharvaris (PHVS) Stock Up 36% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 33,049

Day's Range $19.53 - $21.70

52-Week Range $8.20 - $33.00

Dividend & Yield N/A (N/A)

PHVS Stock Predictions, Articles, and Pharvaris N.V. News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Dec 9, 2022

The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!

Why Is Pharvaris (PHVS) Stock Up 62% Today?

By William White, InvestorPlace Writer Dec 8, 2022

Pharvaris (PHVS) stock is heading higher on Thursday following the release of positive results from a Phase 2 clinical study.

Pharvaris rises as FDA lifts hold on hereditary angioedema candidate (NASDAQ:PHVS)

From Seeking Alpha Jan 22, 2024

Shares of Swiss biotech Pharvaris (PHVS) rise as U.S. regulators lift clinical hold on testing for its proposed treatment for hereditary angioedema (HAE).

Pharvaris stock rises on data for hereditary angioedema drug

From Seeking Alpha Dec 6, 2023

Pharvaris (PHVS) surges 48% pre-market as investors welcome results from its Phase 2 trial for deucrictibant an oral drug for hereditary angioedema. Read more here.

Pharvaris appoints Stefan Abele as Chief Technical Operations officer (NASDAQ:PHVS)

From Seeking Alpha Nov 15, 2023

Pharvaris appoints Dr. Stefan Abele as Chief Technical Operations Officer, responsible for leading chemistry, manufacturing, and supply chain activities as...

Pharvaris GAAP EPS of -€0.58 (NASDAQ:PHVS)

From Seeking Alpha Nov 2, 2023

Pharvaris press release (NASDAQ:PHVS): Q3 GAAP EPS of -€0.58.Cash and cash equivalents of €158 million as of September 30, 2023.

Morgan Stanley ups Pharvaris to overweight, citing HAE drug prospects (NASDAQ:PHVS)

From Seeking Alpha Aug 15, 2023

Morgan Stanley has upgraded Pharvaris (PHVS) to overweight, citing growing confidence in the safety and efficacy of its drug candidate deucrictibant for HAE. Read more here.

Why Shares of Pharvaris N.V. Are Up Tuesday

From The Motley Fool Jun 27, 2023

Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

ADVERTISEMENT